Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8660692rdf:typepubmed:Citationlld:pubmed
pubmed-article:8660692lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:8660692lifeskim:mentionsumls-concept:C0057223lld:lifeskim
pubmed-article:8660692lifeskim:mentionsumls-concept:C0002812lld:lifeskim
pubmed-article:8660692lifeskim:mentionsumls-concept:C0003995lld:lifeskim
pubmed-article:8660692lifeskim:mentionsumls-concept:C0017890lld:lifeskim
pubmed-article:8660692lifeskim:mentionsumls-concept:C1332830lld:lifeskim
pubmed-article:8660692lifeskim:mentionsumls-concept:C0596988lld:lifeskim
pubmed-article:8660692lifeskim:mentionsumls-concept:C0220839lld:lifeskim
pubmed-article:8660692pubmed:issue1lld:pubmed
pubmed-article:8660692pubmed:dateCreated1996-8-15lld:pubmed
pubmed-article:8660692pubmed:abstractTextCytochrome P450 2D6 (CYP2D6) catalyzes the oxidation of substrates with a positively charged nitrogen atom 5-7 angstroms from the site of the oxidation. The active-site topology of CYP2D6 is examined here with phenyl-, 2-naphthyl-, and p-biphenyldiazene, which react with P450 enzymes to form sigma-bonded aryl-iron (Fe-Ar) complexes. Ferricyanide-mediated migration of the aryl group from the iron to the porphyrin nitrogens produces the N-arylprotoporphyrin IX regioisomers (NB:NA:NC:ND, in which the aryl group is bound to the nitrogen of pyrrole rings B, A, C, and D, respectively) in the following ratios (zero means <5%): phenyl, 10:90:00:00; 2-naphthyl, 09:91:00:00; and p-biphenyl, 16:84:00:00. These results suggest that the CYP2D6 active site is open above pyrrole ring A and to a small extent above pyrrole ring B but is closed above pyrrole rings C and D. This geometry differs from those determined by the same method for P450s for which crystal structures are available. Replacement of Asp-301 by a Glu, which preserves the carboxylate side chain, causes no detectable change in the N-aryl porphyrin regioisomer patterns and only minor changes in the catalytic activity. Replacement of Asp-301 by an Asn or Gly, which eliminates the negatively charged side chain, suppresses migration of the aryl groups to pyrrole ring B without impairing migration to pyrrole ring A and virtually abolishes catalytic activity. These results provide a refined model of the active site of CYP2D6. They confirm, furthermore, that the loss of activity observed when Asp-301 is replaced by a neutral residue is due to loss of the charge-pairing interaction with the substrate positive charge and/or subtle structural effects in the vicinity of pyrrole ring B, but not to major structural reorganization of the active site.lld:pubmed
pubmed-article:8660692pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8660692pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8660692pubmed:languageenglld:pubmed
pubmed-article:8660692pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8660692pubmed:citationSubsetIMlld:pubmed
pubmed-article:8660692pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8660692pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8660692pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8660692pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8660692pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8660692pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8660692pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8660692pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8660692pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8660692pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8660692pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8660692pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8660692pubmed:statusMEDLINElld:pubmed
pubmed-article:8660692pubmed:monthJullld:pubmed
pubmed-article:8660692pubmed:issn0003-9861lld:pubmed
pubmed-article:8660692pubmed:authorpubmed-author:TuckerG TGTlld:pubmed
pubmed-article:8660692pubmed:authorpubmed-author:SmithGGlld:pubmed
pubmed-article:8660692pubmed:authorpubmed-author:WolfC RCRlld:pubmed
pubmed-article:8660692pubmed:authorpubmed-author:Ortiz de...lld:pubmed
pubmed-article:8660692pubmed:authorpubmed-author:LennardM SMSlld:pubmed
pubmed-article:8660692pubmed:authorpubmed-author:FLOOGDDlld:pubmed
pubmed-article:8660692pubmed:authorpubmed-author:HayhurstG PGPlld:pubmed
pubmed-article:8660692pubmed:authorpubmed-author:Tschirret-Gut...lld:pubmed
pubmed-article:8660692pubmed:authorpubmed-author:MackmanRRlld:pubmed
pubmed-article:8660692pubmed:issnTypePrintlld:pubmed
pubmed-article:8660692pubmed:day1lld:pubmed
pubmed-article:8660692pubmed:volume331lld:pubmed
pubmed-article:8660692pubmed:ownerNLMlld:pubmed
pubmed-article:8660692pubmed:authorsCompleteYlld:pubmed
pubmed-article:8660692pubmed:pagination134-40lld:pubmed
pubmed-article:8660692pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:8660692pubmed:meshHeadingpubmed-meshheading:8660692-...lld:pubmed
pubmed-article:8660692pubmed:meshHeadingpubmed-meshheading:8660692-...lld:pubmed
pubmed-article:8660692pubmed:meshHeadingpubmed-meshheading:8660692-...lld:pubmed
pubmed-article:8660692pubmed:meshHeadingpubmed-meshheading:8660692-...lld:pubmed
pubmed-article:8660692pubmed:meshHeadingpubmed-meshheading:8660692-...lld:pubmed
pubmed-article:8660692pubmed:meshHeadingpubmed-meshheading:8660692-...lld:pubmed
pubmed-article:8660692pubmed:meshHeadingpubmed-meshheading:8660692-...lld:pubmed
pubmed-article:8660692pubmed:meshHeadingpubmed-meshheading:8660692-...lld:pubmed
pubmed-article:8660692pubmed:meshHeadingpubmed-meshheading:8660692-...lld:pubmed
pubmed-article:8660692pubmed:meshHeadingpubmed-meshheading:8660692-...lld:pubmed
pubmed-article:8660692pubmed:meshHeadingpubmed-meshheading:8660692-...lld:pubmed
pubmed-article:8660692pubmed:meshHeadingpubmed-meshheading:8660692-...lld:pubmed
pubmed-article:8660692pubmed:meshHeadingpubmed-meshheading:8660692-...lld:pubmed
pubmed-article:8660692pubmed:meshHeadingpubmed-meshheading:8660692-...lld:pubmed
pubmed-article:8660692pubmed:meshHeadingpubmed-meshheading:8660692-...lld:pubmed
pubmed-article:8660692pubmed:meshHeadingpubmed-meshheading:8660692-...lld:pubmed
pubmed-article:8660692pubmed:meshHeadingpubmed-meshheading:8660692-...lld:pubmed
pubmed-article:8660692pubmed:meshHeadingpubmed-meshheading:8660692-...lld:pubmed
pubmed-article:8660692pubmed:year1996lld:pubmed
pubmed-article:8660692pubmed:articleTitleActive-site topologies of human CYP2D6 and its aspartate-301 --> glutamate, asparagine, and glycine mutants.lld:pubmed
pubmed-article:8660692pubmed:affiliationDepartment of Pharmaceutical Chemistry, University of California, San Francisco 94143-0446, USA.lld:pubmed
pubmed-article:8660692pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8660692pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:8660692pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8660692lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8660692lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8660692lld:pubmed